
|Videos|May 24, 2017
Underlying Treatment of Myeloproliferative Neoplasms
Underlying Treatment of Myeloproliferative Neoplasms
Advertisement
January 2016
- A 59-year-old male presents to his physician with symptoms of fatigue and abdominal pain lasting 3 months; he also reports increased bruising
- Physical Exam: Spleen is palpable, 6 cm. below left costal margin
- CBC with differential
- RBC; 3.20 x 1012/L
- HGB; 9.3 g/dL
- HCT; 34%
- MCV; 93.1 fL
- WBC; 12.1 x 109/L
- PLT; 247 x 109/L
- PB BLASTS; 0%
- Genetic testing showsJAK2V617Fmutation
- Bone marrow biopsy showed megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































